Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Rhythm ...

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target ...